WO2021208918A1 - 作为egfr抑制剂的三环化合物 - Google Patents
作为egfr抑制剂的三环化合物 Download PDFInfo
- Publication number
- WO2021208918A1 WO2021208918A1 PCT/CN2021/086941 CN2021086941W WO2021208918A1 WO 2021208918 A1 WO2021208918 A1 WO 2021208918A1 CN 2021086941 W CN2021086941 W CN 2021086941W WO 2021208918 A1 WO2021208918 A1 WO 2021208918A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membered
- compound
- group
- alkyl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 949
- 229940121647 egfr inhibitor Drugs 0.000 title abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 184
- 125000000217 alkyl group Chemical group 0.000 claims description 152
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 120
- 229910052736 halogen Inorganic materials 0.000 claims description 80
- 150000002367 halogens Chemical class 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 77
- 125000003545 alkoxy group Chemical group 0.000 claims description 76
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 71
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 67
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 60
- -1 C 1-6 alkane Oxy Chemical group 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 229910052799 carbon Inorganic materials 0.000 claims description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 39
- 125000004992 haloalkylamino group Chemical group 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 37
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 37
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000003003 spiro group Chemical group 0.000 claims description 26
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 25
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 25
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 21
- 125000002883 imidazolyl group Chemical group 0.000 claims description 21
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 21
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 21
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- 125000002541 furyl group Chemical group 0.000 claims description 19
- 125000002971 oxazolyl group Chemical group 0.000 claims description 19
- 125000000335 thiazolyl group Chemical group 0.000 claims description 19
- 125000001544 thienyl group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 18
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 17
- 125000001425 triazolyl group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 150000004677 hydrates Chemical class 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 125000004306 triazinyl group Chemical group 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000006319 alkynyl amino group Chemical group 0.000 claims description 7
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 3
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003943 azolyl group Chemical group 0.000 claims description 2
- PBVFROWIWWGIFK-UHFFFAOYSA-N fluoromethyl-(2-hydroxyethyl)-dimethylazanium Chemical compound FC[N+](C)(C)CCO PBVFROWIWWGIFK-UHFFFAOYSA-N 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 261
- 239000000543 intermediate Substances 0.000 abstract description 145
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 378
- 239000002994 raw material Substances 0.000 description 366
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 333
- 239000000243 solution Substances 0.000 description 308
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 234
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 210
- 230000002829 reductive effect Effects 0.000 description 156
- 238000003756 stirring Methods 0.000 description 156
- 239000012074 organic phase Substances 0.000 description 144
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 135
- 238000005481 NMR spectroscopy Methods 0.000 description 131
- 238000012544 monitoring process Methods 0.000 description 130
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 114
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
- 239000003480 eluent Substances 0.000 description 96
- 238000010898 silica gel chromatography Methods 0.000 description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 82
- 229940125904 compound 1 Drugs 0.000 description 77
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 72
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 239000012071 phase Substances 0.000 description 54
- 239000000203 mixture Substances 0.000 description 52
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- 239000003208 petroleum Substances 0.000 description 41
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- 238000010791 quenching Methods 0.000 description 37
- 230000000171 quenching effect Effects 0.000 description 36
- 239000011259 mixed solution Substances 0.000 description 34
- 239000007858 starting material Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- 102000001301 EGF receptor Human genes 0.000 description 20
- 108060006698 EGF receptor Proteins 0.000 description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000012299 nitrogen atmosphere Substances 0.000 description 13
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 11
- 239000012046 mixed solvent Substances 0.000 description 11
- 125000002950 monocyclic group Chemical group 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 229940126179 compound 72 Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229940125807 compound 37 Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 7
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 239000001099 ammonium carbonate Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 239000008098 formaldehyde solution Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 102200048955 rs121434569 Human genes 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical group ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 5
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 4
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 4
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940125961 compound 24 Drugs 0.000 description 4
- 229940125878 compound 36 Drugs 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical group COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 3
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 3
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical group CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 3
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 3
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 3
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 3
- UUZIGZZNKRYYFL-UHFFFAOYSA-N CP(C)OC(C=CC=C1)=C1N Chemical compound CP(C)OC(C=CC=C1)=C1N UUZIGZZNKRYYFL-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 3
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940127271 compound 49 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 229940127113 compound 57 Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102200048928 rs121434568 Human genes 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 2
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 2
- DFYVFNNIILYXRP-UHFFFAOYSA-N 2,4-dichlorothiophene Chemical compound ClC1=CSC(Cl)=C1 DFYVFNNIILYXRP-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- RAJRANFZSWDUJZ-UHFFFAOYSA-N 2-methylpyrazole-3-carbaldehyde Chemical compound CN1N=CC=C1C=O RAJRANFZSWDUJZ-UHFFFAOYSA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- NPZIPXHYLXTEAB-UHFFFAOYSA-N 3-bromooxolane Chemical group BrC1CCOC1 NPZIPXHYLXTEAB-UHFFFAOYSA-N 0.000 description 2
- ZGOCEDVVZKFHSY-UHFFFAOYSA-N 3-iodopyridin-4-amine Chemical group NC1=CC=NC=C1I ZGOCEDVVZKFHSY-UHFFFAOYSA-N 0.000 description 2
- MINMDCMSHDBHKG-UHFFFAOYSA-N 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(=C(S1)C)N=C1N1CCOCC1 MINMDCMSHDBHKG-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- OVVBXVJFGCFEFK-UHFFFAOYSA-N 6-chloro-2-methoxy-3-nitropyridine Chemical compound COC1=NC(Cl)=CC=C1[N+]([O-])=O OVVBXVJFGCFEFK-UHFFFAOYSA-N 0.000 description 2
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229960003278 osimertinib Drugs 0.000 description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MSGRFBKVMUKEGZ-UHFFFAOYSA-N quinoxalin-6-amine Chemical compound N1=CC=NC2=CC(N)=CC=C21 MSGRFBKVMUKEGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- HQHRAGXKFOTSQE-UHFFFAOYSA-N tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CC(=O)C2 HQHRAGXKFOTSQE-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- ZYGAMJLTPLERBC-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid propan-2-ol Chemical compound B(O)(O)OC(C)(C)C(C)(C)O.C(C)(C)O ZYGAMJLTPLERBC-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- XANVIFOBBVAKCY-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(Br)C(F)=C1 XANVIFOBBVAKCY-UHFFFAOYSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- YZBOZNXACBQJHI-UHFFFAOYSA-N 1-dichlorophosphoryloxyethane Chemical compound CCOP(Cl)(Cl)=O YZBOZNXACBQJHI-UHFFFAOYSA-N 0.000 description 1
- YPACESJCWQAHBF-UHFFFAOYSA-N 1-methylazetidin-3-one Chemical compound CN1CC(=O)C1 YPACESJCWQAHBF-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- QUYJEYSRBCLJIZ-UHFFFAOYSA-N 1-methylpyrazole-3-carbaldehyde Chemical group CN1C=CC(C=O)=N1 QUYJEYSRBCLJIZ-UHFFFAOYSA-N 0.000 description 1
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical group FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- XXDAXUSYDPWTPK-UHFFFAOYSA-N 2-(oxo-lambda5-phosphanylidyne)acetic acid Chemical compound P(=O)#CC(=O)O XXDAXUSYDPWTPK-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- CQOKRSJTVWBAKI-UHFFFAOYSA-N 2-iodopyridin-3-amine Chemical group NC1=CC=CN=C1I CQOKRSJTVWBAKI-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical group NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- DOVLQPYYSCACJX-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-one Chemical compound FC1(F)CC(=O)C1 DOVLQPYYSCACJX-UHFFFAOYSA-N 0.000 description 1
- AIPWPTPHMIYYOX-UHFFFAOYSA-N 3-bromo-2-methylpyridine Chemical compound CC1=NC=CC=C1Br AIPWPTPHMIYYOX-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 1
- ORBHQHXVVMZIDP-UHFFFAOYSA-N 4-bromo-1-methoxy-2-nitrobenzene Chemical group COC1=CC=C(Br)C=C1[N+]([O-])=O ORBHQHXVVMZIDP-UHFFFAOYSA-N 0.000 description 1
- GXAHYXQWHWDEDY-UHFFFAOYSA-N 4-bromo-2-methylpyrazole-3-carbaldehyde Chemical compound CN1N=CC(Br)=C1C=O GXAHYXQWHWDEDY-UHFFFAOYSA-N 0.000 description 1
- UJXICRJJECIZTR-UHFFFAOYSA-N 4-bromo-3-nitrobenzene-1,2-diamine Chemical compound NC1=CC=C(Br)C([N+]([O-])=O)=C1N UJXICRJJECIZTR-UHFFFAOYSA-N 0.000 description 1
- SETOTRGVPANENO-UHFFFAOYSA-N 4-fluoro-2-iodoaniline Chemical compound NC1=CC=C(F)C=C1I SETOTRGVPANENO-UHFFFAOYSA-N 0.000 description 1
- IXENWFQXVCOHAZ-UHFFFAOYSA-N 4-fluoropiperidine;hydrochloride Chemical compound Cl.FC1CCNCC1 IXENWFQXVCOHAZ-UHFFFAOYSA-N 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- RJYWUQWCLZYCTI-UHFFFAOYSA-N 5-iodo-1-methylpyrazole Chemical compound CN1N=CC=C1I RJYWUQWCLZYCTI-UHFFFAOYSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical group O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- YRADCPLKXBTOTI-UHFFFAOYSA-N [2-(oxan-2-yl)pyrazol-3-yl]boronic acid Chemical compound OB(O)C1=CC=NN1C1OCCCC1 YRADCPLKXBTOTI-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- ZSLKGAAJYMFQFI-UHFFFAOYSA-N acetic acid;azidoethane Chemical compound CC(O)=O.CCN=[N+]=[N-] ZSLKGAAJYMFQFI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DLIJPAHLBJIQHE-UHFFFAOYSA-N butylphosphane Chemical compound CCCCP DLIJPAHLBJIQHE-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical group O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- QKZGUSXVOYLZTM-UHFFFAOYSA-N ethyl 5-bromo-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C=1N=CSC=1Br QKZGUSXVOYLZTM-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- VRTQLDFCPNVQNT-UHFFFAOYSA-N methyl 2-bromo-5-methoxybenzoate Chemical group COC(=O)C1=CC(OC)=CC=C1Br VRTQLDFCPNVQNT-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- CQWWONKCVFKXRE-UHFFFAOYSA-N n,n-dimethylethanamine;hydrobromide Chemical compound [Br-].CC[NH+](C)C CQWWONKCVFKXRE-UHFFFAOYSA-N 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 description 1
- GAJDDVONBAWAGB-UHFFFAOYSA-N spiro[2.6]nonyl Chemical group [CH]1CC11CCCCCC1 GAJDDVONBAWAGB-UHFFFAOYSA-N 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JZNWQLLPLOQGOI-UHFFFAOYSA-N tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(=O)C(F)C1 JZNWQLLPLOQGOI-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- RIFXIGDBUBXKEI-UHFFFAOYSA-N tert-butyl 3-oxopiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCCC(=O)C1 RIFXIGDBUBXKEI-UHFFFAOYSA-N 0.000 description 1
- WOEQSXAIPTXOPY-UHFFFAOYSA-N tert-butyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 WOEQSXAIPTXOPY-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention belongs to the field of medicinal chemistry, and specifically relates to novel compounds as selective EGFR inhibitors, pharmaceutical compositions containing the compounds, useful intermediates for preparing the compounds, and the use of the compounds of the present invention to treat cell proliferative diseases, such as cancer. method.
- Lung cancer is the cancer with the highest incidence and mortality rate, and it is a serious threat to human health and life. Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which about 80% are NSCLC.
- SCLC small cell lung cancer
- NSCLC non-small cell lung cancer
- EGFR epidermal growth factor receptor
- epidermal growth factor receptor epidermal growth factor receptor
- fibroblasts fibroblasts
- glial cells glial cells.
- the EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation and differentiation.
- EGFR mutation is also the most common type of mutation in NSCLC patients, especially in Asian populations, which can account for 40% to 50%. Therefore, EGFR has always been one of the most popular targets in the field of drug development.
- EGFR inhibitors on the market are divided into first, second and third generations.
- the first generation is reversible targeted drugs, such as gefitinib, erlotinib, and icotinib.
- the second generation is irreversible targeted drugs, such as afatinib and dacomitinib.
- the first and second-generation targeted drugs have significant effects, most patients will develop resistance after 1-2 years of drug use.
- 50% of the resistance is related to the T790M mutation.
- the third-generation EGFR targeted drug osimertinib can overcome the tumor resistance caused by the T790M mutation and bring better survival benefits to more lung cancer patients.
- the third-generation targeted drugs also inevitably develop resistance, and the main cause of resistance is the C797S mutation.
- the C797S mutation is embodied as the mutation of a cysteine residue to serine. This mutation disrupts the binding of the EGFR protein to the third-generation targeted drugs, thereby failing to prevent the phosphorylation of the EGFR protein and the activation of downstream signaling pathways.
- the present invention is based on solving this problem. produce.
- the purpose of the present invention is to provide a class of tricyclic compounds as selective EGFR inhibitors, pharmaceutical compositions containing the compounds, useful intermediates for the preparation of the compounds, and applications of the compounds in the preparation of cancer drugs.
- the present invention provides a compound represented by formula (I"') or a stereoisomer, tautomer or pharmaceutically acceptable salt, prodrug, hydrate, solvate, or isotope-labeled derivative thereof,
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, 3 -6 membered heterocycloalkyl, C 3-6 cycloalkyloxy, 3-6 membered heterocycloalkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 1- 6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino, C 2-6 alkenylamino and C 2-6 alkynylamino;
- M is selected from N or CR a;
- R a is H, halo, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 heteroalkyl, or C 1-6 haloalkyl;
- Z is selected from N or CR 6 ;
- Z 1 is selected from N or CR 7 ;
- R a and R 1 are cyclized to form a substituted or unsubstituted 5-8 membered heterocyclic group or a 5-8 membered carbocyclic group;
- Ring A is selected from substituted or unsubstituted 5-8 membered heterocyclic group or 5-8 membered carbocyclic group;
- Ring B does not exist or is selected from an aryl group or a 5-6 membered heteroaryl group, a 4-8 membered heterocycloalkyl group or a C 4-8 cycloalkyl group optionally substituted by one or more R 2;
- R 3 and R 4 are each independently selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3- 8 cycloalkyl, 3-8 membered heterocycloalkyl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2 -6 alkenylamino;
- R 3 and R 4 are cyclized to form an aryl group, a C 4-7 cycloalkyl group, a 5-7 membered heterocycloalkyl group, or a 5-6 membered heteroaryl group;
- R b , R c , R d are each independently selected from H, -CN, C 1-3 alkyl, C 1-3 haloalkyl, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, C 5-10 aryl or 5-10 membered heteroaryl;
- R b , R c and the atoms to which they are commonly connected are cyclized into a 5-6 membered heterocycloalkane that is unsubstituted or optionally substituted with one or more C 1-3 alkyl or C 1-3 alkoxy groups base;
- R 6 , R 7 , and R 8 are each independently selected from H, halogen, -CN, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkyl Oxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- R 6 and R 7 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group;
- R 7 and R 8 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group.
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy.
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy.
- M is selected from N or CR a; R a is H, halo, C 1-3 alkyl, C 3-6 cycloalkyl or a C 1-3 haloalkyl.
- R a is H, halo, C 1-3 alkyl, C 3-6 cycloalkyl or a C 1-3 haloalkyl.
- M is selected from N or CH.
- ring B is an aryl group or a 5-6 membered heteroaryl group optionally substituted by one or more R 2 ; the aryl group and 5-6 membered heteroaryl group may be pyrrole Group, furyl, thienyl, pyrazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, triazole, phenyl, pyrimidinyl, pyridyl, pyrazinyl, pyridyl Azinyl or triazinyl.
- R 3 and R 4 are each independently selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1- 6 haloalkoxy, C 3-6 cycloalkyl; or, R 3 and R 4 are cyclized to form phenyl, C 4-7 cycloalkyl, containing one or two heteroatoms selected from O, S and N 5-7 membered heterocycloalkyl or 5-6 membered heteroaryl; preferably, the 5-6 membered heteroaryl may be pyrrolyl, furyl, thienyl, pyrazolyl, thiazolyl, oxazolyl , Isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl or triazinyl.
- R b , R c , and R d are each independently selected from H, C 1-3 alkyl, C 1-3 haloalkyl, C 3-6 cycloalkyl; or, R b ,
- the atom to which R c is commonly attached is cyclized to a 5-6 membered heterocycloalkyl group that is unsubstituted or optionally substituted with one or more C 1-3 alkyl or C 1-3 alkoxy groups.
- R 6 and R 7 are each independently selected from H, halogen, -CN, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C 1- 6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino; or, R 6 and R 7 are cyclized to C 4 -6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl; preferably, the 5-6 membered heteroaryl group can be pyrrolyl, furyl, thienyl, pyrroli
- R 8 is H.
- the present invention provides a compound represented by formula (I") or a stereoisomer, tautomer or pharmaceutically acceptable salt, prodrug, hydrate, solvate, or isotope-labeled derivative thereof,
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, 3 -6 membered heterocycloalkyl, C 3-6 cycloalkyloxy, 3-6 membered heterocycloalkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 1- 6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino, C 2-6 alkenylamino and C 2-6 alkynylamino;
- M is selected from N or CR a;
- R a is H, halo, C 1-3 alkyl, C 3-6 cycloalkyl or a C 1-3 haloalkyl;
- Z is selected from N or CR 6 ;
- Z 1 is selected from N or CR 7 ;
- R a and R 1 are cyclized to form a substituted or unsubstituted 5-8 membered heterocyclic group
- Ring A is selected from substituted or unsubstituted 5-8 membered heterocyclic group or 5-8 membered carbocyclic group;
- Ring B is an aryl group or a 5-6 membered heteroaryl group optionally substituted by one or more R 2 ;
- the aryl group and 5-6 membered heteroaryl group may be pyrrolyl, furyl, thienyl, Pyrazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl or triazinyl;
- R 3 and R 4 are each independently selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3- 8 cycloalkyl, 3-8 membered heterocycloalkyl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2 -6 alkenylamino;
- R 3 and R 4 are cyclized to form an aryl group, a C 4-7 cycloalkyl group, a 5-7 membered heterocycloalkyl group, or a 5-6 membered heteroaryl group;
- R b , R c , R d are each independently selected from H, -CN, C 1-3 alkyl, C 1-3 haloalkyl, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, C 5-10 aryl or 5-10 membered heteroaryl;
- R b , R c and the atoms to which they are connected together are cyclized to a 5-6 membered heterocycloalkyl group
- R 6 , R 7 , and R 8 are each independently selected from H, halogen, -CN, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkyl Oxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- R 6 and R 7 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group;
- R 7 and R 8 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group.
- the present invention provides a compound represented by formula (I') or a stereoisomer, tautomer or pharmaceutically acceptable salt, prodrug, hydrate, solvate, or isotope-labeled derivative thereof,
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, 3 -6 membered heterocycloalkyl, C 3-6 cycloalkyloxy, 3-6 membered heterocycloalkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 1- 6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino, C 2-6 alkenylamino and C 2-6 alkynylamino;
- M is selected from N or CR a;
- R a is H, halo, C 1-3 alkyl, C 3-6 cycloalkyl or a C 1-3 haloalkyl;
- Z is selected from N or CR 6 ;
- R a and R 1 are cyclized to form a substituted or unsubstituted 5-8 membered heterocyclic group
- Ring A is selected from substituted or unsubstituted 5-8 membered heterocyclic group or 5-8 membered carbocyclic group;
- Ring B is an aryl group or a 5-6 membered heteroaryl group optionally substituted by one or more R 2 ;
- the aryl group and 5-6 membered heteroaryl group may be pyrrolyl, furyl, thienyl, Pyrazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl or pyridazinyl;
- R 3 and R 4 are each independently selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3- 8 cycloalkyl, 3-8 membered heterocycloalkyl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2 -6 alkenylamino;
- R 3 and R 4 are cyclized to form an aryl group, a C 4-7 cycloalkyl group, a 5-7 membered heterocycloalkyl group, or a 5-6 membered heteroaryl group;
- R b , R c , R d are each independently selected from H, -CN, C 1-3 alkyl, C 1-3 haloalkyl, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, C 5-10 aryl or 5-10 membered heteroaryl;
- R 6 , R 7 , and R 8 are each independently selected from H, halogen, -CN, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkyl Oxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- R 6 and R 7 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group;
- R 7 and R 8 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group.
- the present invention provides a compound represented by formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt, prodrug, hydrate, solvate, or isotope-labeled derivative thereof,
- R 1 is selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, 3 -6 membered heterocycloalkyl, C 3-6 cycloalkyloxy, 3-6 membered heterocycloalkyloxy, C 2-6 alkenyloxy, C 1-6 alkylamino, C 1-6 Haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- M is selected from N or CR a ;
- R a is H, halogen, C 1-3 alkyl, C 3-6 cycloalkyl or C 1-3 haloalkyl;
- R a and R 1 are cyclized to form a substituted or unsubstituted 5-8 membered heterocyclic group
- Ring A is selected from substituted or unsubstituted 4-8 membered heterocyclic group or 5-8 membered carbocyclic group;
- Ring B is an aryl group or a 5-6 membered heteroaryl group optionally substituted by one or more R 2 ;
- the aryl group and 5-6 membered heteroaryl group may be pyrrolyl, furyl, thienyl, Pyrazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl or pyridazinyl;
- R 3 and R 4 are each independently selected from H, halogen, -CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3- 8 cycloalkyl, 3-8 membered heterocycloalkyl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- R 3 and R 4 are cyclized to form an aryl group, a C 4-7 cycloalkyl group, a 5-7 membered heterocycloalkyl group, or a 5-6 membered heteroaryl group;
- R b , R c , R d are each independently selected from H, -CN, C 1-3 alkyl, C 1-3 haloalkyl, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, C 5-10 aryl or 5-10 membered heteroaryl;
- R 6 , R 7 , and R 8 are each independently selected from H, halogen, -CN, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkyl Oxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino and C 2-6 alkenylamino;
- R 6 and R 7 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group;
- R 7 and R 8 are cyclized to form a C 4-6 cycloalkyl group, a 4-6 membered heterocycloalkyl group, an aryl group, and a 5-6 membered heteroaryl group.
- R 1 is selected from H, halogen, -CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy;
- M is selected from N or CH
- Ring A is selected from substituted or unsubstituted 5-8 membered heterocyclic group or 5-8 membered carbocyclic group;
- Ring B is a 5-6 membered heteroaryl group optionally substituted by one or more R 2 ;
- the 5-6 membered heteroaryl group is pyrrolyl, furyl, thienyl, pyrazolyl, thiazolyl, Oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl or pyridazinyl;
- R 2 is each independently selected from H, C 1-4 alkyl, C 1-4 haloalkyl, -(CH 2 ) r NR c R d , 3-6 membered heterocycloalkyl, C 5-6 arylalkyl Group, wherein said r is arbitrarily selected from 0, 1, 2 or 3, and said 3-6 membered heterocycloalkyl, C 5-6 arylalkyl is optionally substituted by one or more C 1-3 alkane Group or C 1-3 alkoxy substitution;
- R 3 and R 4 are each independently selected from H, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl;
- R 3 and R 4 are cyclized into a 5-6 membered heteroaryl group;
- the 5-6 membered heteroaryl group is pyrrolyl, furyl, thienyl, pyrazolyl, thiazolyl, oxazolyl, isothiazolyl , Isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl or pyridazinyl;
- R b , R c , and R d are each independently selected from H, C 1-3 alkyl, C 1-3 alkoxy, and C 3-6 cycloalkyl;
- R b , R c and the atoms to which they are commonly connected are cyclized into a 5-6 membered heterocycloalkane that is unsubstituted or optionally substituted with one or more C 1-3 alkyl groups or C 1-3 alkoxy groups base;
- R 6 , R 7 , and R 8 are each independently selected from H, halogen, and C 1-3 alkyl;
- R 8 is selected from H, R 6 and R 7 are cyclized to form a 5-6 membered heteroaryl group; the 5-6 membered heteroaryl group is pyrrolyl, furyl, thienyl, pyrazolyl, thiazolyl, oxalanyl Azolyl, isothiazolyl, isoxazolyl, imidazolyl, triazolyl, phenyl, pyrimidinyl, pyridyl, pyrazinyl, or pyridazinyl.
- R 1 is selected from H, halogen, -CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy; preferably, the above-mentioned R 1 is selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl , Methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, trifluoromethyl, trifluoromethoxy, trichloromethyl, trichloromethoxy, 2,2, 2-Trifluoroethoxy; more preferably, the above-mentioned R 1 is selected from methoxy.
- M is selected from N or CH, preferably, M is selected from CH.
- R 2 is selected from H, methyl, ethyl, isopropyl, difluoro Methyl, trifluoromethyl, -CH 2 CH 2 N(CH 3 )CH 3 ,
- R 2 is selected from H, methyl, ethyl, isopropyl, difluoro Methyl, trifluoromethyl; preferably, the above-mentioned R 2 is selected from methyl.
- R 3 and R 4 are each independently selected from H, F, Cl, Br, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, cyclopropyl;
- R 3 and R 4 are each independently selected from H, F, Cl, Br, methyl, difluoromethyl, trifluoromethyl and cyclopropyl; preferably, R 3 is selected from H, R 4 is selected From Cl, Br, methyl, trifluoromethyl.
- R 3 is selected from H
- R 4 is selected from H, F, Cl, Br, Methyl, ethyl, difluoromethyl, trifluoromethyl and cyclopropyl.
- R 3 is selected from H
- R 4 is selected from Cl, Br, and methyl.
- R 3 is selected from H
- R 4 is selected from Br
- R 3 and R 4 are cyclized into a thiophene ring or a pyrrole ring, wherein the thiophene
- the ring and the pyrrole ring may be optionally substituted with a C 1-4 alkyl group.
- R 5 is selected from
- R 5 is selected from
- R 5 is selected from
- R 5 is selected from
- R 5 is selected from
- R 5 and R 6 are cyclized to form
- R 6 , R 7 , and R 8 are each independently selected from H, methyl or Halogen; preferably, each is independently selected from H or methyl.
- R 6 , R 7 , and R 8 are selected from H.
- R 6 and R 8 are selected from H, and R 7 is selected from F.
- R 6 and R 7 or R 7 and R 8 are independently cyclized to form cyclobutane , Cyclopentane, tetrahydropyrrole ring, tetrahydrofuran ring, tetrahydropyran ring, thiophene ring, imidazole ring, pyrazole ring, pyrrole ring, oxazole ring, thiazole ring, isoxazole ring, piperazine ring, isothiazole Ring, benzene ring, pyridine ring, piperidine ring, pyrimidine ring, pyridazine ring, pyrazine ring; preferably, R 6 and R 7 or R 7 and R 8 are independently cyclized to form cyclobutane, pyridine ring or pyrazine Ring; more preferably, R 6 and R 6 and R 7 or R 7 and R 8 are independently cyclized to form cyclobutane, pyridine ring
- the structural unit Selected from R 1 , M and R 2 are as defined above; the above R x is selected from H, -OH, -CN, -NH 2 , halogen, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 Halogenated alkyl, C 3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C 3-8 cycloalkyl-C 1-6 alkyl-, 3-8 membered heterocycloalkyl-C 1-6 alkane Group-, aryl-C 1-6 alkyl-, C 5-13 spirocyclic group, 5-13 membered spiro heterocyclic group; wherein the C 3-8 cycloalkyl group, 3-8 membered heterocycloalkyl group , C 3-8 cycloalkyl-C 1-6 alkyl-, 3-8 membered
- R x When R x is directly connected to the N atom, R x is not -OH, -NH 2 and halogen.
- R x is selected from H, -OH, -CN, -NH 2 , halogen, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C 3-8 cycloalkyl-C 1- 6 alkyl-, 3-8 membered heterocycloalkyl-C 1-6 alkyl-; wherein the C 3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C 3-8 cycloalkyl- C 1-6 alkyl-, 3-8 membered heterocycloalkyl-C 1-6 alkyl-, aryl-C 1-6 alkyl- optionally substituted by one or more R y ; said R y is selected from H, halogen, C 1-6 alkyl, C 1-6 hal
- R x is selected from H, -OH, -CN, -NH 2 , halogen, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1- 4- alkyl-, 3-6 membered heterocycloalkyl-C 1-4 alkyl-, aryl-C 1-6 alkyl-, 7-11 membered spiro heterocyclyl, wherein the C 3-6 ring Alkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, 3-6 membered heterocycloalkyl-C 1-4 alkyl-, aryl-C 1 -6 alkyl-, spiro heterocyclyl is optionally
- R x is selected from H, -OH, -CN, -NH 2 , F, Methyl, ethyl, isopropyl, trifluoroethyl, methylcarbonyl, Ring C is a 4-8 membered heterocycloalkyl group, and ring D is an oxygen-containing 4-8 membered heterocycloalkyl group; m and n are independently 0, 1, 2 or 3; R y is as defined above.
- R x is selected from H, -OH, -CN, -NH 2 , methyl , Ethyl, isopropyl, methylcarbonyl, Ring C is 4-8 membered heterocycloalkyl; m and n are independently 0, 1, 2, or 3.
- R x is selected from H, -OH, -CN, -NH 2 , F, Methyl, ethyl, isopropyl, trifluoroethyl, methylcarbonyl,
- R x is selected from H, methyl, ethyl, isopropyl
- R x is selected from H, methyl, ethyl, isopropyl
- R x is selected from H, methyl, ethyl or isopropyl.
- R x is selected from methyl or isopropyl.
- the structural unit Selected from Wherein, M, R 1 , R 2 , and R x are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotope-labeled derivatives thereof are selected from,
- X 1 and X 2 are each independently selected from N and NR 2 ;
- R 9 and R 10 are independently selected from H, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-8 ring Alkyl, 3-8 membered heterocycloalkyl;
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R x , and M are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotope-labeled derivatives thereof are selected from,
- X 1 and X 2 are each independently selected from N and NR 2 ;
- R 9 and R 10 are independently selected from H, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-8 ring Alkyl, 3-8 membered heterocycloalkyl;
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , and R x are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotope-labeled derivatives thereof are selected from,
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R x , and M are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotope-labeled derivatives thereof are selected from,
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , and R x are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotopically labeled derivatives thereof are selected from,
- R 1 , R 2 , R 4 , R 5 , R x , and M are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotopically labeled derivatives thereof are selected from,
- R 1 , R 2 , R 4 , R 5 , and R x are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotopically labeled derivatives thereof are selected from,
- R 4 , R 5 , R x , and M are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotopically labeled derivatives thereof are selected from,
- R 4 , R 5 , and R x are as defined above.
- the above-mentioned compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotopically labeled derivatives thereof are selected from,
- R 5 and R x are as defined above.
- R 1 , M, R 3 , R 4 , R 5 , R 8 , ring A, Z and Z 1 are as defined above.
- R 1 , M, R 3 , R 4 , R 5 , R 8 , ring A, ring B, Z and Z 1 are as defined above;
- R w and R z are each independently selected from H, -OH, -CN, -NH 2 , halogen, C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 haloalkyl, C 1-6 Halogenated alkoxy, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyloxy, 3-6 membered heterocycloalkyloxy, C 2-6 alkenyloxy , C 2-6 alkynyloxy, C 1-6 alkylamino, C 1-6 haloalkylamino, C 3-6 cycloalkylamino, 3-6 membered heterocycloalkylamino, C 2-6 alkene Alkylamino and C 2-6 alkynylamino.
- the compound or its stereoisomers, tautomers or pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isotope-labeled derivatives including but not limited to:
- the present invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent and excipient.
- the pharmaceutical composition provided by the present invention can be formulated for specific administration routes, such as oral administration, parenteral administration, and rectal administration.
- Oral such as tablets, capsules (including sustained-release or time-release prescriptions), pills, powders, granules, elixirs, tinctures, suspensions (including nano-suspensions, micro-suspensions, spray-dried dispersions) , Syrups and emulsions; sublingual administration; buccal administration; parenteral, for example by subcutaneous, intravenous, intramuscular or intrasternal injection, or infusion techniques (for example, as a sterile injectable aqueous or non-aqueous solution or mixed Suspension); nasally, including administration to the nasal mucosa, for example by inhalation spray; topically, for example in the form of cream or ointment; or transrectally, for example in the form of suppositories. They can be administered alone, but will usually be administered with a pharmaceutical carrier selected according to the chosen route of administration and standard pharmaceutical procedures.
- “Pharmaceutically acceptable carrier” refers to a medium generally acceptable in the art for delivering biologically active agents to animals, especially mammals, and includes, for example, adjuvants, excipients or excipients according to the mode of administration and the nature of the dosage form. Forms such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricating agents Agent and dispersant.
- the pharmaceutically acceptable carrier is formulated according to a large number of factors within the vision of those of ordinary skill in the art.
- compositions containing the agent include both aqueous and non-aqueous media and a variety of solid and semi-solid dosage forms.
- such carriers include many different ingredients and additives, and the inclusion of such additional ingredients in the formulation for various reasons (such as stabilizing the active agent, binder, etc.) is well known to those of ordinary skill in the art.
- the daily oral dose of various active ingredients is in the range of about 0.001-5000 mg per day, or about 1-500 mg, or about 1-250 mg, or about 1- 150 mg, or about 0.5-100 mg, or about 1-50 mg of active ingredient; the most preferred intravenous dose during constant-rate infusion is in the range of about 0.01-10 mg/kg/min.
- the compound of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses of 2, 3, or 4 times a day.
- the dosing regimen for the compound of the present invention can of course be changed according to known factors, such as the pharmacodynamic characteristics of the specific agent and its mode and route of administration, the species, age, sex, health, medical condition and weight of the recipient. , The nature and degree of symptoms, the type of coexisting treatment, the frequency of treatment, the route of administration, the function of the patient’s kidney and liver, and the desired effect.
- the therapeutically effective dose of the compound, pharmaceutical composition, or combination thereof depends on the type, weight, age and individual condition of the subject, the condition or disease to be treated or its severity. A doctor, clinician or veterinarian with ordinary skills can easily determine the effective amount of each active ingredient required to prevent, treat, or inhibit the progress of a disease or disease.
- the present invention also provides the use of the above-mentioned compound or its pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition in the preparation of a medicine for treating cancer.
- Epidermal growth factor receptor EGFR epidermal growth factor receptor
- EGFR signaling pathway plays an important role in the physiological processes of cell growth, proliferation and differentiation.
- EGFR mutations are also the most common type of mutation in NSCLC patients, especially in Asian populations, which can account for 40%-50%. Therefore, in some schemes, the compounds of the present invention can be used to treat cancers caused by high EGFR expression.
- the aforementioned cancers include lymphoma, non-Hodgkin’s lymphoma, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, leukemia, gastric cancer, uterus Endometrial cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), cholangiocarcinoma, kidney cancer, thyroid cancer, anaplastic large cell lymphoma, mesothelioma, Multiple myeloma, melanoma.
- the present invention also provides a method for treating cancer, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I"'), formula (I"), formula (I'), or formula (I) or a pharmaceutically acceptable compound thereof. Accepted salt or pharmaceutical composition as described above.
- the aforementioned cancers include lymphoma, non-Hodgkin’s lymphoma, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, leukemia, gastric cancer, uterus Endometrial cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), cholangiocarcinoma, kidney cancer, thyroid cancer, anaplastic large cell lymphoma, mesothelioma, Multiple myeloma, melanoma.
- the compound of formula (I"'), formula (I"), formula (I') or formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition provided by the present invention is used for the treatment of cancer
- the aforementioned cancers include lymphoma, non-Hodgkin’s lymphoma, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, leukemia, gastric cancer, uterus Endometrial cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), cholangiocarcinoma, kidney cancer, thyroid cancer, anaplastic large cell lymphoma, mesothelioma, Multiple myeloma, melanoma.
- the aforementioned cancer is lung cancer.
- the present invention also provides an intermediate compound represented by formula (V), the intermediate compound or a pharmaceutically acceptable salt thereof, which is selected from:
- R 11 is -NH 2 or -NO 2 ;
- the intermediate compound represented by formula (V), the intermediate compound or a pharmaceutically acceptable salt thereof is selected from,
- R 1 , R 2 , R 11 , and R x are as defined above.
- the intermediate compound represented by formula (V), the intermediate compound or a pharmaceutically acceptable salt thereof is selected from,
- R 11 and R x are as defined above.
- the compound of the present invention has a good inhibitory effect on EGFR (L858R/T790M/C797S) kinase, and has a weaker inhibitory effect on wild-type EGFR kinase, indicating that the compound of the present invention has better kinase activity and selectivity.
- the compound of the present invention has a good inhibitory effect on the cell proliferation of Ba/F3 Del19/T790M/C797S EGFR triple mutant cell line and Ba/F3 L858R/T790M/C797S EGFR triple mutant cell line; inhibition of EGFR wild-type cell line A431
- the weaker effect indicates that the compound of the present invention has good cell activity and selectivity.
- Figure 1 is a graph (mm 3 ) of the tumor growth curve of each group of animals in the in vivo pharmacodynamic research experiment.
- Figure 2 is a graph (g) of the body weight of each group of animals in the in vivo drug efficacy research experiment.
- pharmaceutically acceptable means that it is suitable for use in contact with human and animal tissues within the scope of reasonable medical judgment without excessive toxicity, irritation, allergic reactions or other problems or complications, and a reasonable benefit/risk ratio Comparable compounds, materials, compositions and/or dosage forms.
- pharmaceutically acceptable salt refers to a derivative prepared from a compound of the present invention with a relatively non-toxic acid or base. These salts can be prepared during the synthesis, isolation, and purification of the compound, or the free form of the purified compound can be used alone to react with a suitable acid or base.
- the compound contains relatively acidic functional groups, it reacts with alkali metals, alkaline earth metal hydroxides or organic amines to obtain alkali addition salts, including cations based on alkali metals and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, etc. , And non-toxic ammonium, quaternary ammonium and amine cations.
- the compound contains a relatively basic functional group, it reacts with an organic acid or an inorganic acid to obtain an acid addition salt.
- the compound provided by the present invention also includes the form of a prodrug, which means that the compound of the parent compound of the above formula is rapidly converted in vivo, and is converted to the compound of the present invention by chemical or biochemical methods in an in vivo or in vitro environment, for example, with the help of blood Hydrolysis.
- the compounds of the present invention can exist in unsolvated as well as solvated forms, and solvated forms include hydrate forms. Generally speaking, the solvated form is equivalent to the unsolvated form, and is also encompassed within the scope of the present invention.
- the compounds of the present invention exist geometric isomers and stereoisomers, such as cis-trans isomers, enantiomers, diastereomers, and racemic mixtures and other mixtures, all of which belong to Within the scope of the present invention.
- diastereomer refers to a stereoisomer whose molecule has two or more chiral centers and the relationship between the molecules is non-mirror image.
- cis-trans isomer refers to the configuration in which the double bond or the single bond of the ring-forming carbon atom cannot rotate freely in the molecule.
- wedge-shaped solid line keys And wedge-shaped dashed key Represents the absolute configuration of a three-dimensional center, with a straight solid line key And straight dashed key Indicates the relative configuration of the three-dimensional center.
- the carbon atom is a chiral carbon atom, and the structure represents an optically pure compound with the carbon atom in the (R) configuration or (S) configuration, and a mixture thereof.
- stereoisomers of the compounds of the present invention can be prepared by chiral synthesis or chiral reagents or other conventional techniques.
- an enantiomer of a compound of the present invention can be prepared by asymmetric catalysis technology or chiral auxiliary derivatization technology.
- chiral resolution technology a single stereo configuration compound can be obtained from the mixture.
- it can be directly prepared with chiral starting materials.
- the separation of optically pure compounds in the present invention is usually completed by preparative chromatography, and a chiral chromatographic column is used to achieve the purpose of separating chiral compounds.
- optically pure or “enantiomerically enriched” means that the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than Equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8 %, or greater than or equal to 99.9%.
- the absolute configuration of the compound can be confirmed by conventional technical means in the art.
- single crystal X-ray diffraction method can also confirm the absolute configuration of the compound through the chiral structure of the raw material and the reaction mechanism of asymmetric synthesis.
- the compounds marked as "absolute configuration not determined” are usually resolved into single isomers from racemate compounds by chiral preparative HPLC or SFC, and then characterized and tested.
- the present invention also includes isotopically labeled compounds, including isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H, 3 H, 13 C, 11 C, 14 C, 15 N, and 18 O, respectively. , 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl.
- the compounds of the present invention containing the above-mentioned isotopes and/or other isotopes of other atoms all fall within the scope of the present invention.
- pharmaceutically acceptable carrier refers to a medium generally acceptable in the art for delivering biologically active agents to animals, especially mammals, and includes, for example, adjuvants and excipients according to the mode of administration and the nature of the dosage form. Or excipients, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavors, fragrances, antibacterial agents, antifungal agents , Lubricants and dispersants.
- the pharmaceutically acceptable carrier is formulated according to a large number of factors within the vision of those of ordinary skill in the art.
- compositions containing the agent include both aqueous and non-aqueous media and a variety of solid and semi-solid dosage forms.
- such carriers include many different ingredients and additives. For various reasons (such as stabilizing the active agent, adhesives, etc.) such additional ingredients included in the prescription are well known to those of ordinary skill in the art. .
- excipient generally refers to the carrier, diluent and/or medium required to formulate an effective pharmaceutical composition.
- an effective preventive or therapeutic amount refers to a compound of the present invention or a pharmaceutically acceptable salt thereof in a sufficient amount to treat a disorder with a reasonable effect/risk ratio suitable for any medical treatment and/or prevention.
- the total daily dosage of the compound represented by formula I of the present invention or its pharmaceutically acceptable salt and composition must be determined by the attending physician within the scope of reliable medical judgment.
- the specific therapeutically effective dose level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound used; the specific composition used; The age, weight, general health, gender, and diet of the patient; the time of administration, route of administration and excretion rate of the specific compound used; duration of treatment; drugs used in combination or concurrently with the specific compound used; and Similar factors well known in the medical field.
- the practice in the art is that the dose of the compound starts from a level lower than the level required to obtain the desired therapeutic effect, and the dose is gradually increased until the desired effect is obtained.
- the dose of the compound represented by formula I of the present invention or a pharmaceutically acceptable salt thereof for mammals, especially humans can range from about 0.001 to 1000 mg/kg body weight/day, for example, between about 0.01 to 100 mg/kg.
- Body weight/day for example, between about 0.01-10 mg/kg body weight/day.
- optionally substituted means that it can be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrarily realized on the basis of chemical realization. For example, the term “optionally substituted”"Optionally substituted by one or more R 2 "means that it may be substituted by one or more R 2 or not by R 2 .
- any variable (such as R 2 ) occurs more than once in the composition or structure of a compound, its definition in each case is independent. For example, if a group is substituted with 0-2 R 2 , the group can optionally be substituted with up to two R 2 , and R 2 has independent options in each case.
- n 0 means that the linking group is a single bond, that is, -OCH 3 .
- the substituent can be bonded to any atom on the ring.
- the structural unit It means that the substituent R 1 can be substituted at any position on the benzene ring.
- substituents do not indicate through which atom they are connected to the compounds included in the general formula of the chemical structure but are not specifically mentioned, such substituents may be bonded through any of its atoms.
- pyrazole as a substituent means that any carbon atom on the pyrazole ring is connected to the substituted group; when it appears in the structure or When, it means that the atom is a bonded atom, for example and Both indicate that the N atom on the morpholine ring is a bonding atom.
- ring refers to saturated, partially saturated or unsaturated monocyclic and polycyclic rings, and “polycyclic” includes bicyclic, spiro, fused or bridged rings.
- Representative “ring” includes substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl or heteroaryl.
- hetero means substituted or unsubstituted heteroatoms and the oxidized forms of heteroatoms.
- the heteroatoms are generally selected from N, O, S, and the oxidized forms generally include NO, SO, S(O) 2 , and nitrogen atoms can be Is substituted, that is, NR (R is H or other substituents defined in the text); the number of atoms on the ring is usually defined as the number of ring members, for example, "3-6 membered heterocycloalkyl" refers to 3-6 A ring composed of four atoms, each ring optionally contains 1 to 3 heteroatoms, that is, N, O, S, NO, SO, S(O) 2 or NR, and each ring is optionally R The group is substituted, and R is a group as defined in the text.
- carbocyclic or “carbocyclyl” means a stable ring structure composed of carbon atoms. They can be monocyclic, bicyclic or tricyclic, and they can be saturated, partially unsaturated or Unsaturated (aromatic). Among them, any of the above-mentioned carbocyclic rings may be fused to one or more aromatic rings and aromatic heterocyclic rings to form bicyclic, tricyclic and other polycyclic rings.
- ring A may be a 5-8 membered carbocyclic group, examples of which include but are not limited to R 1 , R 2 , R x , and M are groups defined in the text.
- heterocycle or “heterocyclic group” means a stable monocyclic, bicyclic or tricyclic ring containing heteroatoms or heteroatoms, which may be saturated, partially unsaturated or unsaturated ( Aromatic), they contain carbon atoms and 1, 2, 3 ring heteroatoms independently selected from N, O, S, NO, SO, S(O) 2 or NR, wherein any of the above heterocycles may be fused
- One or more aromatic rings and aromatic heterocyclic rings form bicyclic, tricyclic and other polycyclic rings.
- the structural unit In the ring A may be a 5-8 membered heterocyclic group, examples of which include but are not limited to R 1 , R 2 , R x , and M are groups defined in the text.
- aryl refers to an unsaturated, usually aromatic, hydrocarbon group, which may be a single ring or multiple rings fused together.
- a C 5-10 aryl group is preferred, a C 5-8 aryl group is more preferred, and a monocyclic C 5-6 aryl group is most preferred; examples of aryl groups include, but are not limited to, phenyl and naphthyl.
- heteroaryl means a stable monocyclic or polycyclic aromatic hydrocarbon containing at least one heteroatom (N, O, S, NO, SO, S(O) 2 or NR) . It is preferably a 5-membered or 6-membered monocyclic heteroaryl group.
- heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidinyl.
- alkyl is used to denote a linear or branched saturated hydrocarbon group.
- C 1-6 alkyl more preferably C 1-3 alkyl
- examples of alkyl include, but are not limited to methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, pentyl Base, isopentyl, neopentyl, n-hexyl, etc.
- heteroalkyl refers to an alkyl group in which one or more carbon atoms are replaced by heteroatoms, the heteroatoms being selected from B, O, N, and S, where nitrogen and sulfur atoms are optionally oxidized, Nitrogen heteroatoms are optionally quaternized, including but not limited to "alkoxy", “alkylamino” and “alkylthio", etc.; examples of “heteroalkyl” include, but are not limited to -OCH 3 ,- OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH(CH 3 ) 2 , -N(CH 3 ) 2 , -CH 2 -CH 2 -O-CH 3 , -CH 2 -CH 2 -NH- CH 3 , -CH 2 -CH 2 -N(CH 3 )-CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 ,
- alkenyl refers to an alkyl group having one or more carbon-carbon double bonds. C 2-8 alkenyl is preferred. Examples of alkenyl include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, hexenyl and the like.
- alkynyl refers to an alkyl group having one or more carbon-carbon triple bonds.
- a C 2-8 alkynyl group is preferred, and examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl and the like.
- halogen means a fluorine, chlorine, bromine or iodine atom.
- haloalkyl refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen atoms.
- C 1-6 haloalkyl more preferably C 1-3 haloalkyl
- examples of haloalkyl include but are not limited to monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2trichloroethyl, etc.
- alkoxy refers to an alkyl group connected through an oxygen bridge, that is, a group obtained by substituting a hydrogen atom in a hydroxyl group with an alkyl group.
- a C 1-6 alkoxy group is preferable, and a C 1-3 alkoxy group is more preferable.
- alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentyloxy Group, n-hexyloxy.
- cycloalkyloxy refers to a cycloalkyl group connected through an oxygen bridge, that is, a group obtained by substituting a cycloalkyl group for a hydrogen atom in a hydroxyl group.
- the cycloalkyloxy group is preferably a 3-7 membered, 4-7 membered, or 5-7 membered cycloalkoxy group.
- Examples of cycloalkyloxy include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy.
- haloalkoxy refers to an alkoxy group in which one or more hydrogen atoms are replaced by halogen atoms.
- haloalkoxy include, but are not limited to, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy.
- cycloalkyl refers to a saturated monocyclic or polycyclic hydrocarbon group.
- the cycloalkyl group is preferably a 3-8 membered monocyclic alkyl group, more preferably a 3-6 membered monocyclic alkyl group.
- monocyclic alkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl , Cycloheptyl, cyclooctyl.
- heterocycloalkyl refers to monoheterocycloalkyl and polyheterocycloalkyl groups containing a certain number of heteroatoms in the ring, and the heteroatoms are generally selected from N, O, S, NO, SO, S (O) 2 and NR.
- the heterocycloalkyl group is preferably a 3-8 membered monoheterocycloalkyl group, more preferably a 3-6 membered monoheterocycloalkyl group. Examples of these monoheterocycloalkyl groups include, but are not limited to, oxirane and tetrahydropyrrolyl.
- spirocyclyl refers to a bicyclic or polycyclic hydrocarbon group that shares one carbon atom between two monocyclic rings.
- the spiro ring group is preferably a 5-13 membered spiro ring group, a 6-12 membered spiro ring group, or a 7-11 membered spiro ring group.
- the 6-12 membered spiro ring group means that the spiro ring skeleton structure consists of 6-12 atoms.
- spirocyclic groups include but are not limited to spiro[2.2]pentyl, spiro[2.3]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, spiro[2.6]nonyl, spiro[3.3 ]Heptyl, spiro[3.4]octyl, spiro[3.5]nonyl, spiro[3.6]decyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[4.6]undecyl, spiro[ 5.5]Undecyl, spiro[5.6]dodecyl, spiro[6.6]tridecyl, spiro[6.7]tetradecyl;
- spiroheterocyclic group refers to a spirocyclic group in which one or more carbon atoms in the spirocyclic skeleton structure are replaced by heteroatoms, and the heteroatoms are selected from N, O, and S.
- the spiro heterocyclic group is preferably a 5-13 membered spiro heterocyclic group, a 6-12 membered spiro heterocyclic group, or a 7-11 membered spiro heterocyclic group.
- spiroheterocyclic groups include, but are not limited to, 2-oxa-7-azaspiro[5.3]nonane-7-yl, 2-oxa-7-azaspiro[4.4]nonane-7-yl, 2-oxa-6-azaspiro[3.3]heptane-6-yl, 2-oxa-8-azaspiro[4.5]decane-8-yl, 1,4,9-triazaspiro [5.5]Undecane-9-yl, 3-oxa-9-azaspiro[5.5]undecane-9-yl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,7-diazaspiro[5.3]nonane-7-yl, 2,7-dioxaspiro[5.3]nonyl, 3,9-diazaspiro[5.5]undec-3-yl , 1-oxa-4,9-diazaspiro[5.5]undecane-9-yl
- n is 0, 1, 2 or 3;
- R b is a group defined in the text.
- the name of the title compound is transformed through the structure of the compound with the help of Chemdraw. If there is an inconsistency between the compound name and the compound structure, it can be determined by integrating relevant information and reaction routes; if it cannot be confirmed by other means, the given compound structural formula shall prevail.
- the preparation methods of some of the compounds in the present invention refer to the preparation methods of the aforementioned similar compounds. Those skilled in the art should know that when using or referring to the cited preparation methods, the feed ratio of the reactants, the reaction solvent, the reaction temperature, etc. can be appropriately adjusted according to the difference of the reactants.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those well known to those skilled in the art Equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- the structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or/and liquid-mass spectrometry (LC-MS).
- NMR chemical shift ( ⁇ ) is given in units of parts per million (ppm).
- NMR is measured with BrukerAVANCE III HD 400 or BrukerAVANCE III HD 300 nuclear magnetic instrument, and the determination solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ) ,
- the internal standard is tetramethylsilane (TMS).
- the liquid mass spectrometry LC-MS is measured with SHIMADZU LCMS-2020 mass spectrometer (the ion source is electrospray ionization).
- HPLC determination uses SHIMADZU LC-20AP XR and SPD-M20A high pressure liquid chromatography.
- the thin-layer chromatography silica gel plate uses Yantai Xinnuo Chemical GF254 silica gel plate.
- the specification used for TLC is 0.15mm ⁇ 0.20mm.
- Column chromatography generally uses 200 ⁇ 300 mesh silica gel in Chenghua Chemical as a carrier.
- the starting materials in the examples of the present invention are known and can be bought on the market, or can be synthesized by using or following methods known in the art.
- compound 1A-1 (3 g, 12 mmol) was dissolved in 1,4-dioxane (20 mL). Subsequently, double pinacol borate (3.3g, 13mmol), potassium acetate (2.4g, 24mmol) and [1,1'-bis(diphenylphosphino)ferrocene] were sequentially added to the reaction solution Palladium dichloride (0.88 g, 1.2 mmol). The reaction system was heated to 80°C and stirring was continued for 16 hours. After TLC monitoring showed that the raw material disappeared, the reaction solution was cooled to room temperature and quenched by adding water (100 mL).
- the mixed solution was extracted with ethyl acetate (100 mL ⁇ 3 times), and the organic phases were combined.
- the organic phase was washed with saturated brine (100 mL ⁇ 3 times), then dried over anhydrous sodium sulfate, filtered, and finally concentrated under reduced pressure.
- compound 1B-1 (40 g, 147.6 mmol) was dissolved in N,N-dimethylformamide (400 mL). Subsequently, dimethylphosphine oxide (17.3g, 221.4mmol), palladium acetate (3.3g, 14.7mmol), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene were sequentially added to the above reaction (12.8 g, 22.1 mmol) and N,N-diisopropylethylamine (38.1 g, 295.1 mmol). The reaction solution was heated to 120° C. and stirring was continued for 16 hours.
- compound 1B-2 (5 g, 22.6 mmol) was dissolved in N,N-dimethylformamide (100 mL). Subsequently, sodium hydride (60%, 1.99g, 49.8mmol) was added to the above reaction solution in batches at 0°C and stirring was continued at this temperature for 30 minutes; Chloro-5-bromopyrimidine (6.18g, 27.1mmol), the reaction solution was raised to room temperature and stirring was continued for 2 hours. After LCMS monitoring showed that the starting material disappeared, the reaction solution was quenched by adding saturated aqueous ammonium chloride solution (600 mL).
- Triethyl phosphorylacetate (61.1 g, 273 mmol) was dissolved in tetrahydrofuran (120 mL). Subsequently, under a nitrogen atmosphere and at 0°C, sodium hydride (60%, 10.9 g, 273 mmol) was added to the reaction solution and stirring was continued at this temperature for 30 minutes. A solution of 1-methyl-1H-pyrazole-5-carbaldehyde (20 g, 182 mmol) in tetrahydrofuran (100 mL) was added to the reaction solution. The reaction system was raised to room temperature and stirring was continued for 1.5 hours.
- compound 1C-4 500 mg, 2.22 mmol was dissolved in N,N-dimethylformamide (4 mL). Subsequently, sodium hydride (60%, 69 mg, 1.7 mmol) was added to the above reaction solution. The reaction solution was continuously stirred at 0°C for 30 minutes. Then, methyl iodide (329 mg, 2.3 mmol) was added to the above reaction solution. The reaction system was raised to room temperature and stirring was continued for 2 hours. After LCMS monitoring showed that the raw materials disappeared, saturated aqueous ammonium chloride solution (20 mL) was added to the reaction solution for quenching.
- the raw material was replaced with 3A-2 (12 g, 53 mmol), and 9 g of compound 3A was prepared.
- Methanesulfonyl methylamine (34.8 g, 319 mmol) and o-fluoronitrobenzene (30 g, 212.6 mmol) were dissolved in acetonitrile (400 mL). Subsequently, cesium carbonate (138.6 g, 425 mmol) was added to the above reaction solution and stirring was continued at room temperature for 16 hours. After LCMS monitoring showed that the raw materials disappeared, water (300 mL) was added to the reaction solution for quenching.
- the raw material was replaced with 4A-1 (15 g, 65 mmol) to prepare 12 g of compound 4A-2.
- the raw material was replaced with 7A (80 mg, 0.27 mmol), and 111 mg of the formate of compound 7 was prepared.
- the raw material was replaced with 8A-3 (750 mg, 2.4 mmol) to obtain 470 mg of compound 8A-4.
- the raw material was replaced with 9A-4 (100 mg, 0.33 mmol) to prepare 80 mg of compound 9A.
- reaction solution was purified and purified by a reversed-phase C18 column under the following conditions: chromatographic column 40g C18 reversed-phase column; mobile phase, water (containing 10mM ammonium bicarbonate) and acetonitrile; flow rate, 35mL/min; gradient, Within 20 minutes, acetonitrile rose from 5% to 40%; detection wavelength, 254nm.
- chromatographic column 40g C18 reversed-phase column mobile phase, water (containing 10mM ammonium bicarbonate) and acetonitrile
- flow rate 35mL/min
- gradient Within 20 minutes, acetonitrile rose from 5% to 40%
- detection wavelength 254nm.
- the product was collected and lyophilized under reduced pressure to obtain 70 mg of compound 10A-2.
- the raw material was replaced with 10A-2 (70 mg, 0.19 mmol) to prepare 50 mg of compound 10A-3.
- the raw material was replaced with 10A-3 (50 mg, 0.15 mmol) to prepare 50 mg of compound 10A.
- compound 9A-4 (100 mg, 0.33 mmol) was dissolved in tetrahydrofuran (2 mL). Subsequently, borane-dimethyl sulfide solution (251 mg, 3.31 mmol) was added to the above reaction solution and stirring was continued at room temperature for 16 hours. After the disappearance of the raw materials monitored by LCMS, methanol (5 mL) was added to the reaction solution for quenching. After heating the mixed solution to 60°C and continuing to stir for 1 hour, it was cooled to 0°C, a white solid precipitated, filtered and dried to obtain 60 mg of compound 11A-1.
- the raw material was replaced with 11A-1 (125 mg, 0.43 mmol) to obtain 100 mg of compound 11A.
- the raw material was replaced with 12A-1 (80 mg, 0.24 mmol), and 70 mg of compound 12A was prepared.
- the raw material was replaced with 15A-1 (80 mg, 0.25 mmol) to obtain 66 mg of compound 15A.
- the raw material was replaced with 6A-4 (100 mg, 0.25 mmol) to obtain 70 mg of compound 16A.
- the raw material was replaced with 17A (60 mg, 0.2 mmol), and 21 mg of compound 17 was prepared.
- the raw material was replaced with 18A-2 (70 mg, 0.22 mmol), and 55 mg of compound 18A was prepared.
- the raw materials were replaced with 18A (50 mg, 0.18 mmol) and 7A (52 mg, 0.18 mmol) to prepare 20 mg of compound 18.
- the raw material was replaced with 19A-1 (150 mg, 0.5 mmol) to obtain 100 mg of compound 19A.
- the raw materials were replaced with 19A (60 mg, 0.22 mmol) and 2A (79 mg, 0.22 mmol) to prepare 33 mg of compound 20.
- the raw material was replaced with 21A-1 (11 g, 43.3 mmol) to obtain 5.3 g of compound 21A-2.
- compound 21A-2 (3.7 g, 17 mmol) was dissolved in N,N-dimethylformamide (50 mL). Then at 0°C, sodium hydride (60%, 2.6g, 66mmol) was added to the reaction solution and stirring was continued for 30 minutes, then cyclopropanesulfonyl chloride (7g, 50mmol) was added dropwise to the reaction solution. The reaction system was raised to room temperature and stirring was continued for 2 hours. After LCMS monitoring showed that the raw materials disappeared, saturated aqueous ammonium chloride solution (50 mL) was added to the reaction solution for quenching. The mixture was extracted with ethyl acetate (100 mL ⁇ 3 times), and the organic phases were combined.
- compound 21A-5 (950mg, 2.8mmol), tert-butyl carbamate (488mg, 4.2mmol), cesium carbonate (1.8g, 5.6mmol), methanesulfonic acid (2-dicyclohexylphosphino) -2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (235mg, 0.28mmol) and 2-dicyclohexylphosphorus-2,4,6-triisopropylbiphenyl (132mg, 0.28mmol) were dissolved in 1,4-dioxane (10mL).
- the raw material was replaced with compound 21A-7 (620 mg, 2.2 mmol) to prepare 700 mg of compound 21A.
- compound 6A-4 (100 mg, 0.36 mmol) was dissolved in N,N-dimethylformamide (3 mL). Then, at 0°C, sodium hydride (60%, 22 mg, 0, 5 mmol) was added to the reaction solution and stirring was continued for 30 minutes, then cyanogen bromide (386 mg, 3.6 mmol) was added to the reaction solution. The reaction system was raised to room temperature and stirring was continued for 3 hours. After LCMS monitoring showed that the raw materials disappeared, the reaction solution was purified by a reversed-phase C18 column.
- chromatographic column 40g C18 reverse phase column; mobile phase: water (containing 10mM ammonium bicarbonate) and acetonitrile; flow rate: 35mL/min; gradient: within 20 minutes, acetonitrile rises from 10% to 80%; detection wavelength : 254nm.
- the product was collected and lyophilized under reduced pressure to obtain 65 mg of compound 23A-1.
- the raw material was replaced with 23A-1 (55 mg, 0.18 mmol), and 50 mg of compound 23A was prepared.
- compound 2 120mg, 0.21mmol
- vinyl boronic acid pinacol ester 63 mg, 0.41mmol
- palladium acetate 5mg, 0.02mmol
- 2-biscyclohexylphosphine-2',6' -Dimethoxybiphenyl 13mg, 0.03mmol
- potassium phosphate 131mg, 0.62mmol
- the reaction system was heated to 85°C and stirring was continued for 4 hours. After LCMS monitoring showed that the starting material disappeared, the reaction solution was cooled to room temperature and concentrated under reduced pressure.
- the raw materials were replaced with 2A (162 mg, 0.45 mmol) and 16A (110 mg, 0.45 mmol) to prepare 15 mg of compound 28.
- triphenylphosphine 129 mg, 0.5 mmol was dissolved in tetrahydrofuran (2 mL).
- diethyl azodicarboxylate 9 mg, 0.56 mmol was added to the reaction solution and continue stirring at 0°C for 1 hour (until a milky white turbid liquid is formed).
- Compound 29A-3 90 mg, 0.31 mmol was added to the reaction solution and stirring was continued at room temperature for 4 hours.
- the raw material was replaced with 29A-4 (35 mg, 0.13 mmol), and 20 mg of compound 29A was prepared.
- compound 2 (300mg, 0.52mmol), cyclopropylboronic acid (133mg, 1.55mmol), potassium phosphate (328mg, 1.55mmol), palladium acetate (12mg, 0.05mmol) and tricyclohexylphosphine (14mg ,0.05mmol) was dissolved in a mixed solvent of toluene (2mL) and water (0.4mL). The reaction system was heated to 100°C and stirring was continued for 24 hours. After LCMS monitoring showed that the raw materials disappeared, the reaction solution was added to water (10 mL). The mixture was extracted with ethyl acetate (30 mL ⁇ 3 times), and the organic phases were combined.
- the raw material was replaced with 31A-4 (85 mg, 0.29 mmol), and 65 mg of compound 31A was prepared.
- the raw material was replaced with 31A (65 mg, 0.25 mmol), and 30 mg of compound 31 was prepared.
- the raw material was replaced with 32B (130 mg, 0.24 mmol), and 80 mg of compound 32C was prepared.
- compound 33A-1 (60 g, 317.4 mmol) was dissolved in ethanol (500 mL). Then sodium borohydride (6 g, 158.7 mmol) was added to the reaction solution in batches. The reaction system was raised to room temperature and stirring was continued for 1 hour. After LCMS monitoring showed that the raw materials disappeared, the reaction solution was concentrated under reduced pressure. Water (300 mL) was added to the mixture to dilute, and the pH was adjusted to 6 with concentrated hydrochloric acid. The mixture was extracted with ethyl acetate (300 mL ⁇ 3 times), and the organic phases were combined. The organic phase was washed with saturated brine (200 mL ⁇ 3 times), then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 60 g of compound 33A-2.
- the raw material was replaced with 33A-10 (40 mg, 0.15 mmol) to obtain 30 mg of compound 33A.
- the raw materials were replaced with 34A (202 mg, 0.56 mmol) and 2A (200 mg, 0.56 mmol) to prepare 200 mg of compound 34.
- 6-Aminoquinoxaline (10 g, 68.89 mmol) was dissolved in concentrated sulfuric acid (20 mL). Under the condition of 0° C., potassium nitrate (9.054 g, 89.55 mmol) was added to the reaction solution in batches, and stirring was continued at this temperature for 30 minutes. After LCMS monitoring showed that the raw materials disappeared, the reaction solution was poured into ice water (100 g). Adjust its pH to 8 with 1M aqueous sodium hydroxide solution. The mixed solution was extracted with ethyl acetate (200 mL ⁇ 2 times), and the organic phases were combined.
- the raw material was replaced with 35A-1 (50 mg, 0.26 mmol) to prepare 40 mg of compound 35A.
- the raw material was replaced with 35A (200 mg, 0.52 mmol), and 130 mg of compound 35B was prepared.
- the raw material was replaced with 35B (130 mg, 0.22 mmol), and 76 mg of compound 35C was prepared.
- the mixed solution was extracted with ethyl acetate (100 mL ⁇ 2 times), and the organic phases were combined.
- the organic phase was washed with saturated brine (100 mL ⁇ 3 times), then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the raw materials were replaced with 38A (90 mg, 0.37 mmol) and 2A (133 mg, 0.37 mmol) to prepare 10 mg of compound 38.
- the raw material was replaced with 24B (700 mg, 2.72 mmol) to prepare 400 mg of compound 40A-1.
- the raw materials were replaced with 40A (65 mg, 0.24 mmol) and 2A (86 mg, 0.24 mmol) to prepare 10 mg of compound 40.
Abstract
Description
Claims (39)
- 式(I”’)所示的化合物,或其立体异构体、互变异构体或药学上可接受的盐、前药、水合物、溶剂合物、同位素标记衍生物,其中,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 2-6炔基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基和C 2-6炔基氨基;M选自N或者CR a;Z选自N或者CR 6;Z 1选自N或者CR 7;R a为H、卤素、C 1-6烷基、C 3-6环烷基、C 1-6杂烷基或C 1-6卤代烷基;或者,R a与R 1环化成取代或未被取代5-8元杂环基或5-8元碳环基;环A选自取代或未被取代的5-8元杂环基或5-8元碳环基;环B不存在或者选自任选被一个或多个R 2所取代的芳基或5-6元杂芳基、4-8元杂环烷基或C 4-8环烷基;R 2各自独立的选自H、卤素、-CN、-C(=O)R b、-C(=O)NR bR c、-S(=O) 2R b、-S(=O)(=NR c)R b、-NH 2、-OH、-SH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 5-6芳基、C 5-6芳基烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、 C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基或-(CH 2) rNR cR d,r任意地选自0、1、2或3;其中,R 2中所述的C 3-6环烷基、3-6元杂环烷基、C 5-6芳基、C 5-6芳基烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基或C 2-6烯基氨基任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代;R 3、R 4各自独立的选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-8环烷基、3-8元杂环烷基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 3与R 4环化成芳基、C 4-7环烷基、5-7元杂环烷基或5-6元杂芳基;R 5选自取代或未被取代的-NH 2、-C(=O)NR bR c、-S(=O) 2R b、-P(=O)R bR c、-P(=O)R bNR cR d、-P(=O)R bOR c、-P(=O)OR bOR c、-P(=S)R bR c、-P(=S)R bNR cR d、-P(=S)R bOR c、-P(=S)OR bOR c、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-N=S(=O)R bR c或R bN=S(=O)R c-、-NR bC(O)R c或R cS(=NR b)(=O)NR d-;R b、R c、R d各自独立的选自H、-CN、C 1-3烷基、C 1-3卤代烷基、C 3-6环烷基、C 4-6杂环烷基、C 5-10芳基或5-10元杂芳基;或者,R b、R c与其共同连接的原子环化为未取代的或任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代的5-6元杂环烷基;R 6、R 7、R 8各自独立的选自H、卤素、-CN、-OH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 2-6烯基、C 2-6炔基、C 3-6环烷基、3-6元杂环烷基、5-6元杂芳基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 5与R 6环化成含有-P(=O)(R b)-、-P(=S)(R b)-、-N(R b)S(=O) 2-、-S(=O) 2N(R b)-或-S(=O) 2的4-7元环;或者,R 6与R 7环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基;或者,R 7与R 8环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基。
- 如权利要求1的式(I”’)所示的化合物,其中,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基;优选地,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基。
- 如权利要求1的式(I”’)所示的化合物,其中,M选自N或者CR a,其中R a为H、卤素、C 1-3烷基、C 3-6环烷基或C 1-3卤代烷基;优选地,M选自N或CH。
- 如权利要求1的式(I”’)所示的化合物,其中,环A选自取代或未被取代的5-8元碳环基或者含有1或2个选自O、S和N的杂原子的5-8元杂环基;优选地,环A中可包含双键;或者优选地,环A上的1或2个环原子可任选地被-C(=O)、-N(=O)、-S(=O)、-S(=O) 2替换,环A还可任选地被一个或多个R x基团取代,其中所述R x选自H、-OH、-CN、-NH 2、卤素、C 1-6烷基羰基、C 1-6烷基、C 1-6卤代烷基、C 3-8环烷基、3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-、芳基-C 1-6烷基-、C 5-13螺环基、5-13元螺杂环基;其中所述C 3-8环烷基、3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-、芳基-C 1-6烷基-、C 5-13螺环基、5-13元螺环基元螺杂环基任选的被一个或多个R y所取代;其中,所述R y选自H、卤素、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 3-8环烷基、4-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、4-8元杂环烷基-C 1-6烷基-、5-10元芳基、5-10元杂芳基。
- 如权利要求1的式(I”’)所示的化合物,其中,环B为任选被一个或多个R 2所取代的芳基或5-6元杂芳基;所述的芳基、5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基、哒嗪基或三嗪基。
- 如权利要求1的式(I”’)所示的化合物,其中,R 2各自独立的选自H、卤素、-CN、-C(=O)R b、-S(=O) 2R b、-S(=O)(=NR c)R b、-NH 2、-OH、-SH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 5-6芳基、C 5-6芳基烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基或-(CH 2) rNR cR d,r任意地选自0、1、2或3;其中,R 2中所述的3-6元杂环烷基、C 5-6芳基烷基任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代。
- 如权利要求1的式(I”’)所示的化合物,其中,R 3、R 4各自独立的选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷 基;或者,R 3与R 4环化成苯基、C 4-7环烷基、含有1个或2个选自O、S和N的杂原子的5-7元杂环烷基或5-6元杂芳基;优选地,所述5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基、哒嗪基或三嗪基。
- 如权利要求1的式(I”’)所示的化合物,其中,R 5选自取代或未被取代的-NH 2、-C(=O)NR bR c、-S(=O) 2R b、-P(=O)R bR c、-P(=O)R bNR cR d、-P(=O)R bOR c、-P(=O)OR bOR c、-P(=S)R bR c、-P(=S)R bNR cR d、-P(=S)R bOR c、-P(=S)OR bOR c、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-N=S(=O)R bR c、R bN=S(=O)(R c)-、-NR bC(O)R c;或者,R 5与R 6环化成含有-P(=O)(R b)-、-P(=S)(R b)-、-N(R b)S(=O) 2-、-S(=O) 2N(R b)-或-S(=O) 2的4-7元环。
- 如权利要求1的式(I”’)所示的化合物,其中,R b、R c、R d各自独立的选自H、C 1-3烷基、C 1-3卤代烷基、C 3-6环烷基;或者,R b、R c与其共同连接的原子环化为未取代的或任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代的5-6元杂环烷基。
- 如权利要求1的式(I”’)所示的化合物,其中,R 6和R 7各自独立的选自H、卤素、-CN、-OH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 2-6烯基、C 2-6炔基、C 3-6环烷基、3-6元杂环烷基、5-6元杂芳基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 6与R 7环化成C 4-6环烷基、4-6元杂环烷基、苯基、5-6元杂芳基;优选地,所述5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基、哒嗪基或三嗪基。
- 如权利要求1的式(I”’)所示的化合物,其中,R 8为H。
- 式(I”)所示的化合物,或其立体异构体、互变异构体或药学上可接受的盐、前药、水合物、溶剂合物、同位素标记衍生物,其中,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 2-6炔基氧基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基和C 2-6炔基氨基;M选自N或者CR a;R a为H、卤素、C 1-3烷基、C 3-6环烷基或C 1-3卤代烷基;Z选自N或者CR 6;Z 1选自N或者CR 7;或者,R a与R 1环化成取代或未被取代的5-8元杂环基;环A选自取代或未被取代的5-8元杂环基或5-8元碳环基;环B为任选被一个或多个R 2所取代的芳基或5-6元杂芳基;所述的芳基、5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基、哒嗪基或三嗪基;R 2各自独立的选自H、卤素、-CN、-C(=O)R b、-S(=O) 2R b、-S(=O)(=NR c)R b、-NH 2、-OH、-SH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 5-6芳基、C 5-6芳基烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基或-(CH 2) rNR cR d,r任意地选自0、1、2或3;R 3、R 4各自独立的选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷 基、C 1-6卤代烷氧基、C 3-8环烷基、3-8元杂环烷基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 3与R 4环化成芳基、C 4-7环烷基、5-7元杂环烷基或5-6元杂芳基;R 5选自取代或未被取代的-NH 2、-C(=O)NR bR c、-S(=O) 2R b、-P(=O)R bR c、-P(=O)R bNR cR d、-P(=O)R bOR c、-P(=O)OR bOR c、-P(=S)R bR c、-P(=S)R bNR cR d、-P(=S)R bOR c、-P(=S)OR bOR c、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-N=S(=O)R bR c或R bN=S(=O)(R c)-、-NR bC(O)R c;R b、R c、R d各自独立的选自H、-CN、C 1-3烷基、C 1-3卤代烷基、C 3-6环烷基、C 4-6杂环烷基、C 5-10芳基或5-10元杂芳基;或者,R b、R c与其共同连接的原子环化为5-6元杂环烷基;R 6、R 7、R 8各自独立的选自H、卤素、-CN、-OH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 2-6烯基、C 2-6炔基、C 3-6环烷基、3-6元杂环烷基、5-6元杂芳基、C 1-6烷基氨基、C 1-6卤代烷氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 5与R 6环化成含有-P(=O)(R b)-、-P(=S)(R b)-、-N(R b)S(=O) 2-、-S(=O) 2N(R b)-或-S(=O) 2的4-7元环;或者,R 6与R 7环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基;或者,R 7与R 8环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基。
- 式(I’)所示的化合物,或其立体异构体、互变异构体或药学上可接受的盐、前药、水合物、溶剂合物、同位素标记衍生物,其中,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 2-6炔基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基、C 2-6烯基氨基和C 2-6炔基氨基;M选自N或者CR a;Z选自N或者CR 6;R a为H、卤素、C 1-3烷基、C 3-6环烷基或C 1-3卤代烷基;或者,R a与R 1环化成取代或未被取代5-8元杂环基;环A选自取代或未被取代的5-8元杂环基或5-8元碳环基;环B为任选被一个或多个R 2所取代的芳基或5-6元杂芳基;所述的芳基、5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基或哒嗪基;R 2各自独立的选自H、卤素、-CN、-C(=O)R b、-S(=O) 2R b、-S(=O)(=NR c)R b、-NH 2、-OH、-SH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 5-6芳基、C 5-6芳基烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;R 3、R 4各自独立的选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-8环烷基、3-8元杂环烷基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 3与R 4环化成芳基、C 4-7环烷基、5-7元杂环烷基或5-6元杂芳基;R 5选自取代或未被取代的-NH 2、-C(=O)NR bR c、-S(=O) 2R b、-P(=O)R bR c、-P(=O)R bNR cR d、-P(=O)R bOR c、-P(=O)OR bOR c、-P(=S)R bR c、-P(=S)R bNR cR d、-P(=S)R bOR c、-P(=S)OR bOR c、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-N=S(=O)R bR c或R bN=S(=O)R c-;R b、R c、R d各自独立的选自H、-CN、C 1-3烷基、C 1-3卤代烷基、C 3-6环烷基、C 4-6杂环烷基、C 5-10芳基或5-10元杂芳基;R 6、R 7、R 8各自独立的选自H、卤素、-CN、-OH、C 1-6烷基、C 1-6烷氧基、 C 1-6卤代烷基、C 1-6卤代烷氧基、C 2-6烯基、C 2-6炔基、C 3-6环烷基、3-6元杂环烷基、5-6元杂芳基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 5与R 6环化成含有P(=O)R b的4-7元环;或者,R 6与R 7环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基;或者,R 7与R 8环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基。
- 式(I)所示的化合物,或其立体异构体、互变异构体或药学上可接受的盐、前药、水合物、溶剂合物、同位素标记衍生物,其中,R 1选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基、C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;M选自N或者CR a;R a为H、卤素、C 1-3烷基、C 3-6环烷基或C 1-3卤代烷基;或者,R a与R 1环化成取代或未被取代5-8元杂环基;环A选自取代或未被取代的4-8元杂环基或5-8元碳环基;环B为任选被一个或多个R 2所取代的芳基或5-6元杂芳基;所述的芳基、5-6元杂芳基可以为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基或哒嗪基;R 2各自独立的选自H、卤素、-CN、-C(=O)R b、-S(=O) 2R b、-S(=O)(=NR c)R b、 -NH 2、-OH、-SH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基氧基、3-6元杂环烷基氧基和C 2-6烯基氧基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;R 3、R 4各自独立的选自H、卤素、-CN、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-8环烷基、3-8元杂环烷基、C 1-6烷基氨基基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 3与R 4环化成芳基、C 4-7环烷基、5-7元杂环烷基或5-6元杂芳基;R 5选自取代或未被取代的-NH 2、-C(=O)NR bR c、-S(=O) 2R b、-P(=O)R bR c、-P(=O)R bNR cR d、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-N=S(=O)R bR c或R bN=S(=O)R c-;R b、R c、R d各自独立的选自H、-CN、C 1-3烷基、C 1-3卤代烷基、C 3-6环烷基、C 4-6杂环烷基、C 5-10芳基或5-10元杂芳基;R 6、R 7、R 8各自独立的选自H、卤素、-CN、-OH、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 2-6烯基、C 2-6炔基、C 3-6环烷基、3-6元杂环烷基、5-6元杂芳基、C 1-6烷基氨基、C 1-6卤代烷基氨基、C 3-6环烷基氨基、3-6元杂环烷基氨基和C 2-6烯基氨基;或者,R 5与R 6环化成含有P(=O)R b的4-7元环;或者,R 6与R 7环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基;或者,R 7与R 8环化成C 4-6环烷基、4-6元杂环烷基、芳基、5-6元杂芳基。
- 如权利要求1-14任一项所述的化合物,其中,R 1选自H、卤素、-CN、C 1-3烷基、C 1-3烷氧基、C 1-3卤代烷基、C 1-3卤代烷氧基;M选自N或者CH;环A选自取代或未被取代的5-8元杂环基或5-8元碳环基;环B为任选被一个或多个R 2所取代的5-6元杂芳基;所述的5-6元杂芳基为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基或哒嗪基;R 2各自独立的选自H、C 1-4烷基、C 1-4卤代烷基、-(CH 2) rNR cR d、3-6元杂环 烷基、C 5-6芳基烷基,其中所述r任意地选自0、1、2或3,所述3-6元杂环烷基、C 5-6芳基烷基任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代;R 3、R 4各自独立的选自H、卤素、C 1-4烷基、C 1-4卤代烷基、C 3-6环烷基;或者,R 3与R 4环化成5-6元杂芳基;所述5-6元杂芳基为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基或哒嗪基;R 5选自-C(=O)NR bR c、-P(=O)R bR c、-P(=S)R bR c、-S(=O) 2NR bR c、R bS(=O) 2NR c-、-NR bC(O)R c;R b、R c、R d各自独立的选自H、C 1-3烷基、C 1-3烷氧基、C 3-6环烷基;或者,R b、R c与其共同连接的原子环化为未取代的或任选地被一个或多个C 1-3烷基或C 1-3烷氧基取代的5-6元杂环烷基;或者,R 5与R 6环化成含有-P(=O)(R b)-、-P(=S)(R b)-、-N(R b)S(=O) 2-、-S(=O) 2N(R b)-或-S(=O) 2的4-7元环;R 6、R 7、R 8各自独立的选自H、卤素、C 1-3烷基;或者,R 8选自H,R 6与R 7环化成5-6元杂芳基;所述5-6元杂芳基为吡咯基、呋喃基、噻吩基、吡唑基、噻唑基、噁唑基、异噻唑基、异噁唑基、咪唑基、三氮唑基、苯基、嘧啶基、吡啶基、吡嗪基或哒嗪基。
- 如权利要求1-15任一项所述的化合物,其中所述M选自N或CH;优选地,M为CH。
- 如权利要求1-16任一项所述的化合物,其中所述R 1选自H、卤素、-CN、C 1-3烷基、C 1-3烷氧基、C 1-3卤代烷基、C 1-3卤代烷氧基;优选地,其中所述R 1选自H、甲基、乙基、正丙基、异丙基、正丁基、甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、三氟甲基、三氟甲氧基、三氯甲基、三氯甲氧基、2,2,2-三氟乙氧基;更优选地,其中所述R 1选自甲氧基。
- 如权利要求1-18任一项所述的化合物,其中所述R 3、R 4各自独立的选自H、F、Cl、Br、CN、甲基、乙基、异丙基、甲氧基、乙氧基、异丙氧基、二氟甲基、三氟甲基、2,2,2-三氟乙基、环丙基;优选地,其中所述R 3选自H,R 4各自独立的选自H、F、Cl、Br、甲基、二氟甲基、三氟甲基、环丙基;更优选地,其中所述R 3选自H,R 4独立的选自F、Cl、Br、甲基、乙基、二氟甲基、三氟甲基;更优选地,其中所述R 3选自H,R 4选自Cl、Br、甲基;还更优选地,其中所述R 3选自H,R 4选自Br。或者,其中所述R 3、R 4环化为噻吩环、吡咯环,其中所述噻吩环与吡咯环可任选地被C 1-4烷基所取代。
- 权利要求1-20任一项所述的化合物,其中所述R 6、R 7、R 8各自独立的选自H、甲基或卤素;或者,R 6、R 8选自H,R 7选自F;或者,R 6、R 7、R 8各自独立地选自H或甲基,优选为H;或者,其中所述R 6与R 7或者R 7与R 8独立地环化成环丁烷、环戊烷、四氢吡咯环、四氢呋喃环、四氢吡喃环、噻吩环、咪唑环、吡唑环、吡咯环、恶唑环、噻唑环、异恶唑环、哌嗪环、异噻唑环、苯环、吡啶环、哌啶环、嘧啶环、哒嗪环、吡嗪环;优选地,R 6与R 7或者R 7与R 8独立地环化成环丁烷、吡啶环或吡嗪环;更优选地,R 6与R 7独立地环化成吡嗪环。
- 其中,R 1如权利要求1-21任一项所定义;M如权利要求1-21任一项所定义;R 2如权利要求1-21任一项所定义;R x选自H、-OH、-CN、-NH 2、卤素、C 1-6烷基羰基、C 1-6烷基、C 1-6卤代烷基、C 3-8环烷基、3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-、芳基-C 1-6烷基-、C 5-13螺环基、5-13元螺杂环基;其中所述C 3-8环烷基、 3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-、芳基-C 1-6烷基-、C 5-13螺环基、5-13元螺杂环基任选的被一个或多个R y所取代;其中,所述R y选自H、卤素、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 3-8环烷基、4-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、4-8元杂环烷基-C 1-6烷基-、5-10元芳基、5-10元杂芳基。
- 如权利要求22所述的化合物,其中,R x选自H、-OH、-CN、-NH 2、卤素、C 1-6烷基羰基、C 1-6烷基、C 1-6卤代烷基、C 3-8环烷基、3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-;其中所述C 3-8环烷基、3-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、3-8元杂环烷基-C 1-6烷基-、芳基-C 1-6烷基-任选的被一个或多个R y所取代;或者,R x选自H、-OH、-CN、-NH 2、卤素、C 1-6烷基羰基、C 1-6烷基、C 1-6卤代烷基、C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基-C 1-4烷基-、3-6元杂环烷基-C 1-4烷基-、芳基-C 1-6烷基-、7-11元螺杂环基,其中所述C 3-6环烷基、3-6元杂环烷基、C 3-6环烷基-C 1-4烷基-、3-6元杂环烷基-C 1-4烷基-、芳基-C 1-6烷基-、螺杂环基任选的被一个或多个R y所取代;其中,所述R y选自H、卤素、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 3-8环烷基、4-8元杂环烷基、C 3-8环烷基-C 1-6烷基-、4-8元杂环烷基-C 1-6烷基-、5-10元芳基、5-10元杂芳基;优选地,所述R y选自H、卤素、C 1-4烷基、C 1-4卤代烷基、C 1-4烷氧基、C 3-6环烷基-C 1-6烷基-;优选地,R y选自H、F、甲基、乙基、异丙基、甲氧基、 FCH 2CH 2-;其中,当R x与N原子直接相连时,R x不为-OH、-NH 2以及卤素。
- 如权利要求22或23所述的化合物,其中,R x选自H、-OH、-CN、-NH 2、F、甲基、乙基、异丙基、三氟乙基、甲基羰基、 其中,环C为4-8元杂环烷基,环D为含氧的4-8元杂环烷基;m和n独立的为0、1、2或3;R y如权利要求22或23中所定义;优选地,R x选自H、甲基、乙基或异丙基;优选地,R x选自甲基或异丙基。
- 如权利要求1-25任一项所述的化合物,其选自或者其中,X、Y各自独立的选自-C(=O)-、-C=C-、-NR x-、-O-、-CR 9R 10-、-S(=O)-、-S(=O) 2-;X 1、X 2各自独立的选自N、NR 2;R 9、R 10选自H、卤素、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、C 3-8环烷基、3-8元杂环烷基;R 1如权利要求1-25任一项所定义;R 2如权利要求1-25任一项所定义;R 4如权利要求1-25任一项所定义;R 5如权利要求1-25任一项所定义;R 6、R 7如权利要求1-25任一项所定义;R x如权利要求22-25任一项所定义;M,如果存在,则如权利要求1-25任一项所定义。
- 一种药物组合物,其包含权利要求1-31任一项所述的化合物或其药学上可接受的盐,以及药学上可接受的载体、稀释剂或赋形剂。
- 权利要求1-32任一项所述的化合物或其药学上可接受的盐或权利要求32所述的药物组合物在制备治疗癌症药物中的应用。
- 如权利要求33所述的应用,其中癌症包括淋巴瘤、非霍奇金淋巴瘤、卵巢癌、宫颈癌、前列腺癌、结肠直肠癌、乳腺癌、胰腺癌、胶质瘤、胶质母细胞瘤,黑色素瘤、白血病、胃癌、子宫内膜癌、肺癌、肝细胞癌、胃癌、胃肠道间质瘤(GIST)、急性髓细胞白血病(AML)、胆管癌、肾癌、甲状腺癌、间变性大细胞淋巴瘤、间皮瘤、多发性骨髓瘤、黑色素瘤。
- 如权利要求34所述的应用,其中癌症为肺癌。
- 权利要求36-38任一项所述的化合物或其立体异构体、或其药学上可接受 的盐在制备权利要求1-31任一项所述化合物或其立体异构体、互变异构体或药学上可接受的盐、前药、水合物、溶剂合物、同位素标记衍生物中的用途。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/996,265 US20240034743A9 (en) | 2020-04-14 | 2021-04-13 | Tricyclic compounds as egfr inhibitors |
BR112022019888A BR112022019888A2 (pt) | 2020-04-14 | 2021-04-13 | Compostos tricíclicos como inibidores de egfr |
JP2022562485A JP2023522863A (ja) | 2020-04-14 | 2021-04-13 | Egfr阻害剤としての三環式化合物 |
KR1020227039738A KR20230002721A (ko) | 2020-04-14 | 2021-04-13 | Egfr 억제제로서의 삼환계 화합물 |
EP21789436.9A EP4137484A4 (en) | 2020-04-14 | 2021-04-13 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS |
AU2021256157A AU2021256157A1 (en) | 2020-04-14 | 2021-04-13 | Tricyclic compounds as EGFR inhibitors |
CA3171776A CA3171776A1 (en) | 2020-04-14 | 2021-04-13 | Tricyclic compounds as egfr inhibitors |
CN202180027938.0A CN115667226A (zh) | 2020-04-14 | 2021-04-13 | 作为egfr抑制剂的三环化合物 |
MX2022012818A MX2022012818A (es) | 2020-04-14 | 2021-04-13 | Compuestos triciclicos como inhibidores de egfr. |
ZA2022/12150A ZA202212150B (en) | 2020-04-14 | 2022-11-07 | Tricyclic compounds as egfr inhibitors |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010292186 | 2020-04-14 | ||
CN202010292186.8 | 2020-04-14 | ||
CN202010852717 | 2020-08-22 | ||
CN202010852717.4 | 2020-08-22 | ||
CN202110175424 | 2021-02-09 | ||
CN202110175424.1 | 2021-02-09 | ||
CN202110312259.X | 2021-03-24 | ||
CN202110312259 | 2021-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021208918A1 true WO2021208918A1 (zh) | 2021-10-21 |
Family
ID=78083953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/086941 WO2021208918A1 (zh) | 2020-04-14 | 2021-04-13 | 作为egfr抑制剂的三环化合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240034743A9 (zh) |
EP (1) | EP4137484A4 (zh) |
JP (1) | JP2023522863A (zh) |
KR (1) | KR20230002721A (zh) |
CN (1) | CN115667226A (zh) |
AU (1) | AU2021256157A1 (zh) |
BR (1) | BR112022019888A2 (zh) |
CA (1) | CA3171776A1 (zh) |
MX (1) | MX2022012818A (zh) |
WO (1) | WO2021208918A1 (zh) |
ZA (1) | ZA202212150B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023061434A1 (zh) * | 2021-10-14 | 2023-04-20 | 齐鲁制药有限公司 | 一种三环化合物的用途 |
WO2023061433A1 (zh) * | 2021-10-14 | 2023-04-20 | 齐鲁制药有限公司 | 一种egfr抑制剂的多晶型 |
WO2024046405A1 (zh) * | 2022-09-01 | 2024-03-07 | 齐鲁制药有限公司 | 一种egfr激酶抑制剂的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031560A (zh) * | 2004-09-28 | 2007-09-05 | 诺瓦提斯公司 | 用作酪氨酸激酶抑制剂的环状二芳基脲 |
CN101535276A (zh) * | 2006-10-23 | 2009-09-16 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
CN101616895A (zh) * | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9834518B2 (en) * | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US10730887B2 (en) * | 2016-12-12 | 2020-08-04 | Hangzhou Innogate Pharma Co., Ltd. | Compound containing tricyclic heteroaryl group |
-
2021
- 2021-04-13 AU AU2021256157A patent/AU2021256157A1/en active Pending
- 2021-04-13 US US17/996,265 patent/US20240034743A9/en active Pending
- 2021-04-13 WO PCT/CN2021/086941 patent/WO2021208918A1/zh unknown
- 2021-04-13 MX MX2022012818A patent/MX2022012818A/es unknown
- 2021-04-13 CN CN202180027938.0A patent/CN115667226A/zh active Pending
- 2021-04-13 KR KR1020227039738A patent/KR20230002721A/ko unknown
- 2021-04-13 EP EP21789436.9A patent/EP4137484A4/en active Pending
- 2021-04-13 JP JP2022562485A patent/JP2023522863A/ja active Pending
- 2021-04-13 CA CA3171776A patent/CA3171776A1/en active Pending
- 2021-04-13 BR BR112022019888A patent/BR112022019888A2/pt unknown
-
2022
- 2022-11-07 ZA ZA2022/12150A patent/ZA202212150B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031560A (zh) * | 2004-09-28 | 2007-09-05 | 诺瓦提斯公司 | 用作酪氨酸激酶抑制剂的环状二芳基脲 |
CN101535276A (zh) * | 2006-10-23 | 2009-09-16 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
CN101616895A (zh) * | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
Non-Patent Citations (2)
Title |
---|
DATABASE REGISTRY 21 October 2009 (2009-10-21), ANNONYMOUS: "4H-Pyrazolo[3,4-c]quinolin-4-one, 8-amino-5-ethyl-3,5-dihydro-3-methyl- (CA INDEX NAME)", XP055858250, retrieved from STN Database accession no. 1189306-45-3 * |
See also references of EP4137484A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023061434A1 (zh) * | 2021-10-14 | 2023-04-20 | 齐鲁制药有限公司 | 一种三环化合物的用途 |
WO2023061433A1 (zh) * | 2021-10-14 | 2023-04-20 | 齐鲁制药有限公司 | 一种egfr抑制剂的多晶型 |
WO2024046405A1 (zh) * | 2022-09-01 | 2024-03-07 | 齐鲁制药有限公司 | 一种egfr激酶抑制剂的用途 |
Also Published As
Publication number | Publication date |
---|---|
BR112022019888A2 (pt) | 2022-11-22 |
EP4137484A1 (en) | 2023-02-22 |
CA3171776A1 (en) | 2021-10-21 |
MX2022012818A (es) | 2022-11-14 |
EP4137484A4 (en) | 2023-12-20 |
KR20230002721A (ko) | 2023-01-05 |
AU2021256157A1 (en) | 2022-12-15 |
US20230192734A1 (en) | 2023-06-22 |
CN115667226A (zh) | 2023-01-31 |
JP2023522863A (ja) | 2023-06-01 |
US20240034743A9 (en) | 2024-02-01 |
ZA202212150B (en) | 2023-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021052499A1 (zh) | 稠合吡啶酮类化合物及其制备方法和应用 | |
CN110312719B (zh) | 作为jak家族激酶抑制剂的咪唑并吡咯并吡啶 | |
WO2021208918A1 (zh) | 作为egfr抑制剂的三环化合物 | |
CN112679495B (zh) | 雌激素受体调节剂 | |
CN112533929B (zh) | 吲哚类大环衍生物、其制备方法及其在医药上的应用 | |
WO2021031952A1 (zh) | 氧代六元环并嘧啶类化合物,其制法与医药上的用途 | |
CN113272301A (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
TW202140450A (zh) | 用於癌症治療的kras抑制劑 | |
WO2021000885A1 (zh) | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 | |
TW201414737A (zh) | 作爲激酶抑制劑之咪唑并三□甲腈 | |
WO2020238791A1 (zh) | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
WO2016169421A1 (zh) | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 | |
CN107820494A (zh) | 核受体调节剂 | |
CN103459382B (zh) | 用于抑制pask的杂环化合物 | |
CN114728962A (zh) | 血浆激肽释放酶抑制剂及其用途 | |
TW202039474A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法 | |
CN114423758A (zh) | 抗细菌化合物 | |
WO2022268230A1 (zh) | 作为kif18a抑制剂的化合物 | |
CN112979655A (zh) | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 | |
KR20230035036A (ko) | 이중 키나제-브로모도메인 억제제 | |
TW202110831A (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
WO2022194269A1 (zh) | 新型egfr降解剂 | |
WO2022166860A1 (zh) | Pim激酶抑制剂 | |
CN110582495B (zh) | 作为tnf活性的调节剂的稠合五环咪唑衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21789436 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3171776 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019888 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022562485 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227039738 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022019888 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220930 |
|
ENP | Entry into the national phase |
Ref document number: 2021789436 Country of ref document: EP Effective date: 20221114 |
|
ENP | Entry into the national phase |
Ref document number: 2021256157 Country of ref document: AU Date of ref document: 20210413 Kind code of ref document: A |